5731-18-0

Usage

Uses

Used in Pharmaceutical Synthesis:
N-Benzyl-3-pyrrolidinecarboxylic acid is utilized as a building block for the synthesis of various pharmaceuticals and biologically active compounds. Its unique structure and functional groups contribute to the development of new drugs with potential therapeutic benefits.
Used in Pain Management:
As an analgesic, N-Benzyl-3-pyrrolidinecarboxylic acid is used for its pain-relieving properties, offering a potential alternative or adjunct to existing pain management therapies.
Used in Anesthesia:
In the field of anesthesiology, N-Benzyl-3-pyrrolidinecarboxylic acid is studied for its potential as an anesthetic agent, providing a means to induce a state of temporary insensibility to pain during surgical procedures or other medical interventions.
Used in Drug Delivery Systems:
N-Benzyl-3-pyrrolidinecarboxylic acid is employed in the development of drug delivery systems to enhance the efficacy and targeted delivery of pharmaceuticals, potentially improving patient outcomes and treatment compliance.
Used in Asymmetric Synthesis:
As a chiral auxiliary, N-Benzyl-3-pyrrolidinecarboxylic acid is used in asymmetric synthesis to facilitate the production of enantiomerically pure compounds, which are crucial in the pharmaceutical industry for the development of drugs with specific biological activities and reduced side effects.

Upstream product

• 93102-05-7 N-benzyl-N-(methoxymethyl)-N-[(trimethylsilyl)methyl]amine 
• 79-10-7 acrylic acid 
• 17012-21-4 1-benzylpyrrolidine-3-carboxylic acid methyl ester 
• 59378-87-9 pyrrolidine-3-carboxylic acid 
• 72925-15-6 3-ethoxycarbonyl-pyrrolidine 
• 5747-92-2 1-benzyl-3-carboethoxypyrrolidine 

Downstream Products

• 666853-73-2 C₁₆H₂₂N₂O₂ 
• 5731-17-9 1-(Phenylmethyl)-3-pyrrolidinemethanol 
• 188527-21-1 1-((benzyloxy)carbonyl)pyrrolidine-3-carboxylic acid 
• 72925-16-7 1-boc-pyrrolidine-3-carboxylic acid 
• 1233923-95-9 (+/-)-1-benzyl-N-(9-chloro-3,4-dihydro-2H-1,5-benzodioxepin-7-ylmethyl)-N-isobutylpyrrolidine-3-carboxamide 

Relevant academic research and scientific papers

Discovery of novel n-substituted prolinamido indazoles as potent rho kinase inhibitors and vasorelaxation agents

Inhibitors of Rho kinase (ROCK) have potential therapeutic applicability in a wide range of diseases, such as hypertension, stroke, asthma and glaucoma. In a previous article, we described the lead discovery of DL0805, a new ROCK I inhibitor, showing potent inhibitory activity (IC50 6.7 μM). Herein, we present the lead optimization of compound DL0805, resulting in the discovery of 24- and 39-fold more-active analogues 4a (IC50 0.27 μM) and 4b (IC50 0.17 μM), among other active analogues. Moreover, ex-vivo studies demonstrated that 4a and 4b exhibited comparable vasorelaxant activity to the approved drug fasudil in rat aortic rings. The research of a preliminary structure-activity relationship (SAR) indicated that the target compounds containing a β-proline moiety have improved activity against ROCK I relative to analogues bearing an β-proline moiety, and among the series of the derivatives with a β-proline-derived indazole scaffold, the inhibitory activity of the target compounds with a benzyl substituent is superior to those with a benzoyl substituent.

Synthesis and antibacterial activity of the C-7 side chain of 3-aminoquinazolinediones

A novel series of bacterial topoisomerase (3-aminoquinazolinediones) inhibitors are described. The side-chain SAR against Gram-positive and Gram-negative organisms as well as DNA gyrase activity is reported.

Rifamycin derivatives

Novel rifamycin derivatives of formula I (both hydroquinone and corresponding quinone (C1-C4) forms): or their salts, hydrates or prodrugs thereof, wherein: a preferred R comprises hydrogen, acetyl; L is a linker, a preferred linker group elements selected from any combination of 1 to 5 groups shown FIG. 1, provided L is not wherein R1 is H, methyl or alkyl. The inventive compounds exhibit valuable antibiotic properties. Formulations having these compounds can be used in the control or prevention of infectious diseases in mammals, both humans and non-humans. In particular, the compounds exhibit a pronounced antibacterial activity, even against multiresistant strains of microbes.

Angiotensin II antagonists

This invention provides novel heterocyclic derivatives, their pharmaceutical formulations, and their use for antagonizing angiotensin II receptors in mammals.

Angiotensin II antagonist intermediates

This invention provides novel heterocyclic derivatives, their pharmaceutical formulations, and their use for antagonizing angiotensin II receptors in mammals.